secwatch.observer — SEC 8-K summary
======================================

Issuer:     CAPRICOR THERAPEUTICS, INC. (CAPR)
CIK:        0001133869
Form:       8-K
Filed at:   2026-07-14T21:06:03+00:00
Accession:  0001104659-26-083559
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 2.03
LLM model:  deepseek-v4-flash:cloud@v2

Capricor signs lease for 171K sq ft HQ; rent abatement, FDA approval contingency
--------------------------------------------------------------------------------

- Lease for 171,000 rentable sq ft at 9625 Towne Centre Dr, San Diego, as new HQ with manufacturing cleanrooms.
- Initial monthly base rent ~$958K ($5.60/sq ft), escalating 3% annually; 18-month full rent abatement then 6-month partial.
- Lease term 138 months from rent commencement; commencement tied to earlier of FDA approval satisfaction or Dec 31, 2026.
- If FDA approval of Deramiocel for Duchenne muscular dystrophy not obtained by Dec 31, 2026, either party may terminate.
- Security deposit ~$958K in cash or letter of credit; Capricor responsible for taxes, insurance, operating costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133869/000110465926083559/0001104659-26-083559-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133869/000110465926083559/capr-20260709x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-083559

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer